A Randomized, Double-blind, Placebo-controlled, Multicenter, Proof-of-concept, Phase IIA Study of MP1032 Plus Standard of Care vs Standard of Care in the Treatment of Hospitalized Participants With Moderate to Severe COVID-19
Latest Information Update: 12 Jul 2024
At a glance
- Drugs MP 1032 (Primary) ; Remdesivir
- Indications COVID 2019 infections; SARS-CoV-2 acute respiratory disease
- Focus Proof of concept; Therapeutic Use
- Sponsors MetrioPharm
Most Recent Events
- 31 Jan 2024 According to a MetrioPharm media release, data from this study published in The Lancet Regional Health - Europe.
- 31 Jan 2024 Results published in the MetrioPharm Media Release
- 11 Nov 2022 Status changed from recruiting to completed.